Comparison of progestin-primed ovarian stimulation (PPOS) during continuous dienogest administration and GnRH antagonist method in infertility cases complicated by endometriosis: A retrospective cohort Study

Comparison of Progestin-Primed Ovarian Stimulation (PPOS) and GnRH Antagonist Protocols during Continuous Dienogest Administration in Endometriosis-Associated Infertility: A Retrospective Cohort Study - Retrospective Cohort Study Comparing PPOS and GnRH Antagonist Methods during Dienogest Administration

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044076

Enrollment

Registered

2021-05-01

Start date

2021-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Endometriosis-associated infertile women who undergo IVF-ET program. 1) woman who has endometrioid cyst (chocolate cyst) (cyst diam eter smaller than 4cm) diagnosed by imaging. (The patient with endometrial cysts more than 4cm receive the r eduction treatment with operation or medication before IVF-ET start.) 2) woman who give written informed consent before entry into t his study.

Exclusion criteria

Exclusion criteria: 1) Patients who documented cycles with no oocyte retrieved, an y contraindications to ovarian stimulation treatment and 2) patients who has contraindication to DNG, GnRHa, EP, FSH, HMG, HCG 3) Using other hormonal therapy except Dienogest over 2 months before COS 4) Patients who is judged to be inappropriate for this study by th e doctor

Design outcomes

Primary

Measure	Time frame
The clinical pregnancy rate	—

Secondary

Measure	Time frame
1) total amount of FSH/HMG 2) number of growing follicle (<15mm) and mature follicle (<18m m), number of oocyte retrieved 3)the incidence of premature LH surge 4) fertilization rate, implantation rate 5) serum concentration of estradiol and progesterone (on the tri gger day) 6) the incidence of OHSS 7) the viable embryo rate 8) ongoing pregnancy rate, early miscarriage rate, multiple preg nancy rate	—

Measure

Time frame

1) total amount of FSH/HMG 2) number of growing follicle (<15mm) and mature follicle (<18m m), number of oocyte retrieved 3)the incidence of premature LH surge 4) fertilization rate, implantation rate 5) serum concentration of estradiol and progesterone (on the tri gger day) 6) the incidence of OHSS 7) the viable embryo rate 8) ongoing pregnancy rate, early miscarriage rate, multiple preg nancy rate

—

Countries

Japan

Contacts

Public ContactNanako Iwami

Kamiya Ladies Clinic Reproductive therapy

nanakoiwami@gmail.com0112312722

Outcome results